Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07166315

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Axial Spondylarthritis (axSpA) Arthritis Arthritis, Psoriatic Bone Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Psoriatic Arthritis (PsA) Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal National Hospital for Rheumatic Diseases

Bath, Somerset, BA1 3NG, United Kingdom

Location status: Recruiting

Location contact

Clare Davey

CONTACT

[email protected]

01225821800

Dr William Tillett

PRINCIPAL_INVESTIGATOR

About this study

Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
  • Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
  • Participant is aged 18 years or older at enrolment.

Exclusion criteria

-Participation in a clinical trial at enrolment.

Treatment and study plan

observational study

Other

This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Primary outcomes

  1. Number of participants that have achieved Low Disease Activity (LDA) at 12 months.

    Time frame: At 12 months

  2. Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.

    Time frame: At 12 months

  3. Change from baseline in PROM scores at 12 months.

    Time frame: At 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

SpA Extend Team

CONTACT

[email protected]

+441625 577 829

Sponsors and collaborators

Lead sponsor

Adelphi Real World

Industry

Registry information

Official study title

Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 10, 2025
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.